Author Archives: Bruno Quinney

#Artificial intelligence (AI) #Biologics #Drug discovery

Enabling AI in chemistry and biologics discovery

This paid-for advertorial from CDD Vault appeared in DDW Volume 26 – Issue 4, Fall 2025   CDD Vault outlines what to look for in an SDMP across chemistry and biologics using examples from CDD Vault and other leading platforms.  AI and machine learning are accelerating structure-activity relationship (SAR) predictions… Read More

#Exclusive Content

Vaccine
#Vaccines

Editor’s Comment: Listening to the Science

With the news that RFK Jr – America’s Secretary of Health and Human Services – has cancelled around $500 million in funding for mRNA vaccines research, the question arises of how far political opinion can sway both medical research and society’s trust in science.  The decision by RFK Jr has… Read More

#Exclusive Content #Opinion

A laboratory mouse
#Cancer Research Institute #Pancreatic cancer

Scientists discover key protein target to treat pancreatic cancer

Scientists have discovered a key protein that could be targeted with a drug to treat the most common and aggressive form of pancreatic cancer.  The findings, published in Nature, show that blocking the protein SPP1 could stop the spread of the cancer and increase survival… Read More

#News

Influenza
#Cidara #Clinical trial #Influenza

Phase III trial of flu preventative CD388 accelerated  

The Phase III study of CD388, a non-vaccine preventative of seasonal flu, has been accelerated by six months, biotechnology company Cidara Therapeutics has announced.  The planned Phase III study will be a global, multicentre, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single… Read More

#News

#KRAS #Pancreatic cancer

McCormick wins Stephenson Global Prize for ‘innovative’ research 

The inaugural Stephenson Global Prize has been awarded to Dr Frank McCormick for his groundbreaking discoveries into pancreatic cancer.  The Stephenson Global Prize, presented for the first time in Boston, Massachusetts, was established to reward visionary researchers with resources to accelerate discoveries that could change the trajectory… Read More

#News

DDW Highlights: 26 September 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In this week’s news, results from a clinical trial offer hope for the first time that… Read More

#Podcasts

This week in Drug Discovery (22 – 26 September)

News round-up for 22 – 26 September by Bruno Quinney, Content Team at DDW.  Research into Huntington’s disease has made global headlines this week, with clinical trial results at University College London (UCL) showing gene therapy could slow down the disease’s progression. Elsewhere, a big-name drug discovery… Read More

#News

Molecular,Model,Of,Antibody
#Antibody drug conjugate (ADC) #Biotechnology

Synaffix and Qurient Therapeutics reach agreement to develop ADCs

Biotechnology company Synaffix has announced it has entered a licensing agreement with biopharmaceutical company Qurient Therapeutics for the development of a dual-payload antibody-drug conjugates (ADCs).  Dual-payload ADCs are designed to deliver two separate cytotoxic agents with distinct mechanisms of action to target cancer cells, aiming to enhance therapeutic efficacy and… Read More

#Business & Investment #News

Zika virus
#AI #SARS-CoV-2 #virus

New AI-powered database set to accelerate virus research

UK researchers have launched a new platform described as ‘the most comprehensive human virus protein database’ in the world, it has been revealed.  Viro3D, which was developed by researchers at the MRC-University of Glasgow Centre for Virus Research, uses AI to offer new perspectives on viruses, allowing… Read More

#News

Dystrophin muscle protein
#FDA #Sanofi

FDA grants fast track designation to DM1 treatment SAR446268

The US Food and Drug Administration (FDA) has granted fast track designation to SAR446268 for the treatment of non-congenital DM1 myotonic dystrophy type 1 (DM1).  The announcement was made by pharmaceutical company Sanofi, who developed SAR446268 as a one-time gene therapy. Fast track designation will… Read More

#News

#Clinical trial #Treatment-resistant depression

Positive data published on BPL-003 for patients with TRD

Biopharmaceutical company atai Life Sciences has announced positive data from a proof-of-concept study investigating a two-dose induction regimen of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression (TRD).  The open-label Phase IIa study (NCT05660642) enrolled 13 patients with TRD who were not on… Read More

#News

#AI #Drug discovery #Financing

DaltonTx set to build AI-enabled drug discovery platforms

UK-based technology company DaltonTx has announced the completion of a £4 million ($5.4 million) financing round to build adaptive AI-enabled drug discovery platforms.  The company, which exited from stealth, is planning on building platforms giving research teams instant access to AI-enabled drug discovery, bypassing their need for… Read More

#News

#Sub-Saharan Africa #Tropical disease

Global research team aims to tackle tropical disease

A global research team is aiming to tackle schistosomiasis, a neglected tropical disease affecting millions worldwide.  Researchers at the University of Glasgow will lead a large international collaboration with partners from Cameroon, Côte D’Ivoire, Malawi and the UK to better understand why schistosomiasis remains a devastating disease… Read More

#News

X-ray showing colon cancer
#Biopharma #Cancer #FDA

Alnodesertib granted fast track designation by the FDA

The ATR inhibitor alnodesertib has been granted fast track designation by the US Food and Drug Administration (FDA), biopharmaceutical company Artios Pharma Limited has announced.  Alnodesertib is a treatment for adult patients with ATM negative metastatic colorectal cancer (mCRC) in the third-line setting, in combination with a… Read More

#News

Bottles of painkillers
#Painkillers

Research paves way for safer pain relief drugs

New research by scientists at the NYU Pain Research Center could help to develop more selective drugs to treat pain with fewer side effects, it has been revealed.  The research, published in the journal Nature Communications, identified which receptor in prostaglandins, the hormone-like substance targeted… Read More

#News